ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behçet’s Syndrome"

  • Abstract Number: L14 • ACR Convergence 2024

    A Withdrawal Study of Colchicine in Behçet Syndrome

    Basak Sirin1, Sinem Nihal Esatoglu2, Hasan Yazıcı3 and Gulen Hatemi4, 1Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul, Turkey, 3Academic Hospital, Istanbul, Turkey, 4Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul,Türkiye, Istanbul, Turkey

    Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…
  • Abstract Number: 0150 • ACR Convergence 2024

    The Characteristics of a Northern Israeli Cohort of Patients with Behcet’s Syndrome

    Firas Sabbah1, Fadi Hassan2, Rula Daood2, Helana Jeries3, Tamar Hareuveni4, Nimer Abed5 and Mohammad E Naffaa2, 1Rheumatology Unit, Tzafon Medical Center, Poria, Israel, Tiberias, Israel, 2Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, 3Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, 4Ophthalmology department, Galilee Medical Center, Naharyia, Israel, Nahariya, Israel, 5Internal Medicine "B", Galilee Medical Center, Naharyia, Israel, Nahariya

    Background/Purpose: Behcet's syndrome (BS) is a multisystem disease that typically manifests as recurrent oral and genital ulcers, along with skin, eye, gastrointestinal, neurologic and vascular…
  • Abstract Number: 1111 • ACR Convergence 2024

    Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism

    Kessiena Aomreore, Lincoln Medical Center, New york, NY

    Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…
  • Abstract Number: 1118 • ACR Convergence 2024

    The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3 and Omer Pamuk4, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…
  • Abstract Number: 1633 • ACR Convergence 2024

    Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients

    Koichi Sugihara1, Risa Wakiya2, Hiromi Shimada2, Taichi Miyagi2, Yusuke Ushio2, Rina Mino2, Mao Mizusaki3, Hayamasa yamaguchi3, Naoto Manabe3, Shusaku Nakashima2 and Hiroaki dobashi2, 1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, 2Kagawa University, Miki-cho, Kita-gun, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan

    Background/Purpose: Arthritis associated with Behcet's disease (BD) has been reported to be related to patients' quality of life and associated with skin and mucosal lesions.…
  • Abstract Number: 1896 • ACR Convergence 2024

    The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics

    Priyanka Chandratre1, Joht Chandan2, Ben Hammond3, Rasiah Thayakaran3, Samuel Cusworth3, Nicola Adderley3 and Deva Situnayake4, 1The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, 2Institute of Applied Health Research, Birmingham, United Kingdom, 3Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, 4Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom

    Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
  • Abstract Number: 2515 • ACR Convergence 2024

    Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study

    Weiyi Xia1, Jiachen Li1, Tian Liu1 and Yuhui Li2, 1Peking University People’s Hospital, Beijing, China, 2Peking University, BeiJing, China

    Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
  • Abstract Number: 2517 • ACR Convergence 2024

    Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behçet’s Syndrome

    Betul Sarac1, Ayse Kalkanci2, Esra Kilic2, Elif Ayca Sahin2, Yesim Ozguler3 and Gulen Hatemi3, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Gazi University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Gut, oral and genital mucosa microbiome studies in Behçet’s syndrome have shown heterogeneous results including reduced bacterial diversity and decrease in butyrate-producing bacteria. A…
  • Abstract Number: 2518 • ACR Convergence 2024

    Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

    Yesim Ozguler1, Olivier Manches2, Didar Ucar3, Ziyan Lin2, Alireza Khodadadi-Jamayran2, Aristotelis Tsirigos2, Gulen Hatemi1 and Johannes Nowatzky4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2NYU Grossman School of Medicine, New York, NY, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4New York University Grossman School of Medicine, New York, NY

    Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
  • Abstract Number: 2522 • ACR Convergence 2024

    Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event

    Kerem Abacar1, Ayşe Elif Boncukcuoğlu1, Aysun Aksoy2, Derya Kocakaya1, Çagatay Cimşit1, Haner Direskeneli3 and Fatma Alibaz Öner3, 1Marmara University, istanbul, Turkey, 2Alaaddin Keykubat University, Antalya, Turkey, 3Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey

    Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
  • Abstract Number: 2524 • ACR Convergence 2024

    Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis

    Sooah Kim1, Ye Ji Jung2, Joong Kyong Ahn3 and Jiwon Hwang4, 1Environment Science & Biotechnology, Jeonju University, Jeonju, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea, 3Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 4Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea

    Background/Purpose: Oral manifestations can be the initial indicators of systemic diseases such as Behcet’s disease (BD) and Sjogren’s syndrome (PSS). The frequency and presentation of…
  • Abstract Number: 0692 • ACR Convergence 2023

    Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

    Johannes Nowatzky1, Ziyan Lin2, Yesim Ozguler3, Alireza Khodadadi-Jamayran2, Didar Ucar4, Aristotelis Tsirigos5, Gulen Hatemi6 and Olivier Manches7, 1NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, 2NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, 3NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 5NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France

    Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…
  • Abstract Number: 1564 • ACR Convergence 2023

    Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease

    fatma Alibaz-Öner1, Rabia Ergelen2, Seda Kutluğ Ağaçkıran3, Fatma Temiz4, Tulin Ergun5 and Haner Direskeneli6, 1Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Marmara University, School of Medicine, Department of Radiology, Istanbul, Turkey, 3Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, 4Marmara University, School of Medicine, Department of Internal Medicine, Istanbul, Turkey, 5Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, 6Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey

    Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on multi-systemic clinical manifestations after ruling out other potential causes. There is no specific diagnostic…
  • Abstract Number: 0701 • ACR Convergence 2023

    Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study

    Fabricio Benavides1, Alba Herrero-Morant2, Jose Luis Martin-Varillas3, Carmen Alvarez Reguera1, Lara Sanchez-Bilbao4, David Martinez-Lopez5, Raul Fernandez1, Ivan Ferraz Amaro6, Jose Luis Hernandez1 and Ricardo Blanco7, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 3Hospital de Laredo, Laredo, Spain, 4Hospital Universitario Marques de Valdecilla, Santander, Spain, 5Hospital de Sierrallana, Santander, Spain, 6Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 7Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
  • Abstract Number: 2517 • ACR Convergence 2023

    The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

    Erdem Bektas1, Rabia Deniz2, Zeliha Emrence3, Sema Sırma Ekmekci3, Neslihan Abacı3, Shirkhan Amikishiyev4, Yasemin Yalçınkaya4, Bahar Artim Esen4, Murat Inanç5 and Ahmet Gul6, 1Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, 2University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, 3Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology